Lumendi
20 Margaret Street, Fourth Floor
London
W1W 8RS
United Kingdom
Tel: +44-20-3369-8694
Website: http://lumendi.com/
Email: info@lumendi.co.uk
About Lumendi
Lumendi was founded in 2014 as a spin out from Cornell University, NY. Its mission is to:– Develop devices which enable minimally invasive gastrointestinal interventions. – Manufacture and distribute ESP and follow on products ESP+/FAST
ESP is designed to support GI surgeons and gastroenterologists in their efforts to replace a portion of invasive open or laparoscopic surgeries. It enables safe and cost effective minimally invasive procedures.
YEAR FOUNDED:
2014
LEADERSHIP:
CEO: Peter Johann
COO: Mike Parrilla
CFO: William Wick
VP, R&D: Ian Shaw
18 articles about Lumendi
-
Lumendi Files for 510(k) Clearance for Two New Products
5/19/2022
Connecticut-based medical device innovator Lumendi, LLC has announced it has filed for U.S. Food and Drug Administration 510 clearance for DiLumen EZ¹, a single-use, disposable endotherapy device intended for endoscopic mucosal resections and difficult colonoscopies.
-
Lumendi Introduces EZ Glide Hydrophilic Coating for Its DiLumen Endoluminal Interventional Platform (EIP™)
3/29/2021
Connecticut-based medical device innovator Lumendi, LLC (www.lumendi.com) has launched EZ Glide, a proprietary hydrophilic coating applied to the inner sheath of its DiLumen EIP, a double-balloon endoluminal device that aims to safely improve the navigation of the endoscope through the bowel
-
Pioneering Endosurgery New Mission Statement at Lumendi
8/12/2020
Connecticut-based medical device innovator Lumendi, LLC has announced a change in the company’s Mission & Vision statements to better communicate the intended path of its innovative DiLumenTM Endolumenal Interventional Platform to transform the GI landscape from surgical intervention to endolumenal.
-
Lumendi Reports Successful Enrollment Closure of Its DiLumen™ Endolumenal Interventional Platform (EIP™) Study
3/25/2020
A study evaluating endoscopic procedure time removing complex colorectal polyps shows superiority of DiLumen over control group. WESTPORT, Conn.--( BUSINESS WIRE )-- Connecticut-based medical device innovator Lumendi, LLC ( www.lumendi.com ) reports that its 1:1 randomized trial of the DiLumen Endolumenal Interventional Platform (EIP) successfully met the primary endpoint of an IRB-approved 200-patient prospective study. The study evaluates DiLumen’
-
Large Complex Polyps Removed Successfully From Three Patients Without Surgical Intervention Using Lumendi DiLumen C2™
10/21/2019
A large complex sigmoid polyp in a 62-year-old male patient was successfully removed in a 60-minute procedure without surgical intervention using DiLumen C2, a second-generation endoscopic dual balloon colon stabilization accessory that employs two 6mm working channels that accommodate several flexible therapeutic instruments designed to efficiently retract and dissect tissue.
-
Lumendi Receives 510(k) Clearance for DiLumen Ik™ Endolumenal Interventional Knife
8/20/2019
Connecticut-based medical device innovator Lumendi, LLC (http://www.lumendi.com) has announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the DiLumen Ik™ Endolumenal Interventional Knife, a sterile, single-use, disposable monopolar electrosurgical device for cutting, dissecting, and cauterizing tissue within the digestive tract during endoscopic procedures.
-
Lumendi Brands Exclusive Tissue Manipulation Feature for Company’s DiLumen EIP
6/11/2019
DiLumen +DR Dynamic Retraction System Improves Endoscopists’ Ability to Dissect and Ultimately Resect Polyps Without Surgical Intervention
-
Lumendi Receives FDA 510(k) Clearance for Innovative DiLumen™ EIP Device Modification to Improve Tissue Retraction During Therapeutic Endoscopy
11/13/2018
Modification Improves Endoscopists’ Ability to Dissect and Ultimately Resect Polyps Without Surgical Intervention
-
500 Therapeutic Procedures Using DiLumen™ EIP Completed Across U.S., Europe and Asia
10/4/2018
Connecticut-based medical device innovator Lumendi, LLC (http://www.lumendi.com) reports that more than 500 therapeutic procedures by more than 40 endoscopists and colorectal surgeons have been completed with its DiLumen™ EIP technology, continuing to demonstrate the safety, performance and therapeutic benefits of DiLumen.
-
Biotech Movers and Shakers Aug. 27
8/27/2018
Who made a splash in the biotech world this week? Here are some notable people. -
Lumendi Expands Team with New VP of Sales, Michael R. Thomas
8/21/2018
Lumendi, LLC is again expanding its team as Michael R. Thomas joins as Vice President of Sales.
-
Lumendi Opens EU Market for DiLumen EIP™
7/17/2018
Lumendi Ltd. today announced that its subsidiary, Lumendi LLC, has opened the EU market for its DiLumen EIP™, having received CE Certification.
-
Lumendi Receives FDA 510(k) Clearance for DiLumen Is™ Endolumenal Interventional Scissors
5/29/2018
Connecticut-based medical device innovator Lumendi, LLC has announced it has received United States Food and Drug Administration (FDA) 510(k) clearance for the DiLumen Is™ Endolumenal Interventional Scissors.
-
Lumendi Receives FDA 510(k) Clearance for Dilumen C2™
4/23/2018
Second Generation Endoscopic Accessory for Endolumenal Procedures
-
Lumendi Reports Successful Completion of DiLumen EIP First-in-Human Trials
11/16/2017
There were no serious adverse events in any of the study patients.
-
Lumendi's Dilumen Ig Endolumenal Interventional Grasper for Minimally Invasive Endoscopic Therapies Now Available in U.S.
11/10/2017
The DiLumen Ig is a flexible endoscopic tool intended to grasp and manipulate tissue within the digestive tract under direct endoscopic visualization.
-
Lumendi DiLumen EIP Now Available For Endolumenal Therapy
5/8/2017
-
Lumendi Wins FDA Clearance to Market DiLumen for Endolumenal Therapy
12/13/2016